Your browser doesn't support javascript.
loading
Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-ß1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial.
Arabi, Yaseen M; Asiri, Ayed Y; Assiri, Abdullah M; Aziz Jokhdar, Hani A; Alothman, Adel; Balkhy, Hanan H; AlJohani, Sameera; Al Harbi, Shmeylan; Kojan, Suleiman; Al Jeraisy, Majed; Deeb, Ahmad M; Memish, Ziad A; Ghazal, Sameeh; Al Faraj, Sarah; Al-Hameed, Fahad; AlSaedi, Asim; Mandourah, Yasser; Al Mekhlafi, Ghaleb A; Sherbeeni, Nisreen Murad; Elzein, Fatehi Elnour; Almotairi, Abdullah; Al Bshabshe, Ali; Kharaba, Ayman; Jose, Jesna; Al Harthy, Abdulrahman; Al Sulaiman, Mohammed; Mady, Ahmed; Fowler, Robert A; Hayden, Frederick G; Al-Dawood, Abdulaziz; Abdelzaher, Mohamed; Bajhmom, Wail; Hussein, Mohamed A.
Afiliación
  • Arabi YM; College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia. arabi@ngha.med.sa.
  • Asiri AY; Intensive Care Department, Ministry of the National Guard - Health Affairs, ICU 1425, P.O. Box 22490, Riyadh, 11426, Saudi Arabia. arabi@ngha.med.sa.
  • Assiri AM; Prince Mohammed bin Abdulaziz Hospital, Riyadh, Saudi Arabia.
  • Aziz Jokhdar HA; Infection Prevention and Control, Assistant Deputy Minister, Preventive Health, Ministry of Health, Riyadh, Saudi Arabia.
  • Alothman A; Deputy Minister for Public Health, Ministry of Health, Riyadh, Saudi Arabia.
  • Balkhy HH; College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
  • AlJohani S; Department of Medicine, Ministry of the National Guard - Health Affairs, Riyadh, Saudi Arabia.
  • Al Harbi S; College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
  • Kojan S; Department of Infection Prevention and Control, Ministry of the National Guard - Health Affairs, Riyadh, Saudi Arabia.
  • Al Jeraisy M; College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
  • Deeb AM; Department of Pathology and Laboratory Medicine, Ministry of the National Guard - Health Affairs, Riyadh, Saudi Arabia.
  • Memish ZA; College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
  • Ghazal S; Pharmaceutical Care Department, Ministry of the National Guard - Health Affairs, Riyadh, Saudi Arabia.
  • Al Faraj S; College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
  • Al-Hameed F; Department of Medicine, Ministry of the National Guard - Health Affairs, Riyadh, Saudi Arabia.
  • AlSaedi A; College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
  • Mandourah Y; Pharmaceutical Care Department, Ministry of the National Guard - Health Affairs, Riyadh, Saudi Arabia.
  • Al Mekhlafi GA; King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Research Office, Riyadh, Saudi Arabia.
  • Sherbeeni NM; Ministry of the National Guard - Health Affairs, Riyadh, Saudi Arabia.
  • Elzein FE; Prince Mohammed bin Abdulaziz Hospital, Ministry of Health & College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
  • Almotairi A; Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
  • Al Bshabshe A; Prince Mohammed bin Abdulaziz Hospital, Riyadh, Saudi Arabia.
  • Kharaba A; Prince Mohammed bin Abdulaziz Hospital, Riyadh, Saudi Arabia.
  • Jose J; College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.
  • Al Harthy A; Intensive Care Department, Ministry of the National Guard - Health Affairs, Jeddah, Saudi Arabia.
  • Al Sulaiman M; College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.
  • Mady A; Department of Infection Prevention and Control, Ministry of the National Guard - Health Affairs, Jeddah, Saudi Arabia.
  • Fowler RA; Military Medical Services, Ministry of Defense, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
  • Hayden FG; Department of Intensive Care Services, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
  • Al-Dawood A; Infectious Diseases Division, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
  • Abdelzaher M; Infectious Diseases Division, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
  • Bajhmom W; Department of Critical Care Medicine, King Fahad Medical City, Riyadh, Saudi Arabia.
  • Hussein MA; Department of Critical Care Medicine, King Khalid University, Aseer Central Hospital, Abha, Saudi Arabia.
Trials ; 21(1): 8, 2020 Jan 03.
Article en En | MEDLINE | ID: mdl-31900204
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Infecciones por Coronavirus / Ritonavir / Lopinavir / Coronavirus del Síndrome Respiratorio de Oriente Medio / Interferon beta-1b Tipo de estudio: Clinical_trials / Diagnostic_studies Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Trials Asunto de la revista: MEDICINA / TERAPEUTICA Año: 2020 Tipo del documento: Article País de afiliación: Arabia Saudita Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Infecciones por Coronavirus / Ritonavir / Lopinavir / Coronavirus del Síndrome Respiratorio de Oriente Medio / Interferon beta-1b Tipo de estudio: Clinical_trials / Diagnostic_studies Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Trials Asunto de la revista: MEDICINA / TERAPEUTICA Año: 2020 Tipo del documento: Article País de afiliación: Arabia Saudita Pais de publicación: Reino Unido